Efficacy of regional renal nerve blockade in patients with chronic refractory heart failure

Chinese Medical Journal

Volumn 126, Issue 6, 2013, Pages 1076-1080

  Dai, Qi Ming ^a   Fen, Yi ^a   Lu, Jing ^a   Ma, Gen Shan ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

Chronic heart failure; Renal denervation; Sympathetic activity

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; BRAIN NATRIURETIC PEPTIDE; ELECTROLYTE; LIDOCAINE; NEUROHORMONE; RENIN; ROPIVACAINE; SODIUM ION;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DYSPNEA; ECHOCARDIOGRAPHY; EDEMA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; MEAN ARTERIAL PRESSURE; NERVE BLOCK; RADIOIMMUNOASSAY;

AGED; AMIDES; ANESTHETICS, LOCAL; FEMALE; HEART FAILURE; HEART RATE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NERVE BLOCK; TREATMENT OUTCOME;

EID: 84876945141     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20123204     Document Type: Article

References (28)

1. De Bruyne LK. Mechanisms and management of diuretic resistance in congestive heart failure. Postgrad Med J 2003; 79: 268-271.
2. Grassi G, Seravalle G, Quarti-Trevano F, Scopelliti F, Dell'Oro R, Bolla G, et al. Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: characteristics and mechanisms. Hypertension 2007; 49: 535-541.
3. Grassi G, Seravalle G, Bertimeri G, Turri C, Stella ML, Scopelliti F, et al. Sympathetic and reflex abnormalities in heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. Clin Sci (Lond) 2001; 101: 141-146.
4. Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J 2001; 22: 1136-1143.
5. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995;26:1257-1263.
6. Schrier RW. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med 2006; 19: S47-S53.
7. Del Rio-Santiago VJ, Rodnguez-Ospina L, Córdova HR, Vicenty SI. Congestive heart failure and renal complications. BolAsocMedPR2008; 100: 29-37.
8. DiBona GF, Sawin LL. Frequency response of the renal vasculature in congestive heart failure. Circulation 2003; 107: 2159-2164.
9. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001; 96: 132-43.
10. Neuberg GW, Mller AB, O'Connor CM, Belkin RN, Carson PE, Cropp AB, et al. Prospective randomized amlodipine survival evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002; 144: 31-38.
11. Greenwell TJ, Peters JL, Neild GH, Shah PJ. The outcome of renal denervation for managing loin pain haematuria syndrome. BJU Int 2004; 93: 818-821.
12. Durakovic Z, Durakovic A, Durakovic S. The lack of clinical value of laboratory parameters in predicting outcome in acute renal failure. Ren Fail 1989-1990; 11: 213-219.
13. Prince SA, Janssen I, Tranmer JE. Influences of body mass index and waist circumference on physical function in older persons with heart failure. Can J Cardiol 2008; 24: 905-911.
14. Pang PS, Cleland JF, Teerlink JR, Collins SP, Lindsell CJ, Sopko G, et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J 2008; 29: 816-824.
15. Liu PP. Cardiorenal syndrome in heart failure: a cardiologist's perspective. Can J Cardiol 2008; 24: 25B-29B.
16. Grassil G, Arenarel F, Pieruzzil F, Brambillal G, Mancial G. Sympathetic activation in cardiovascular and renal disease. J Nephrol 2009; 22: 190-195.
17. 123I-metaiodobenzylganidine scintigraphy in chronic heart failure. Chin Med J 2010; 123: 2023-2027.
18. Pocock S, Wilhelmsen L, Dickstein K, Francis G, Wittes J. The data monitoring experience in the MOXCON trial. Eur Heart J 2004; 25: 1974-1978.
19. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxomdme in patients with heart failure (MOXCON). Eur J Heart Fail 2003; 5: 659-667.
20. Vink EE, Blankestijn PJ. Evidence and consequences of the central role of the kidneys in the pathophysiology of sympathetic hyperactivity. Front Physiol 2012; 3: 29-35.
21. Ye S, Zhong H, Yanamadala V, Campese VM. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 2002; 15: 717-724.
22. Schlaich MP, Krum H, Sobotka PA. Renal sympathetic nerve ablation: the new frontier in the treatment of hypertension. Curr Hypertens Rep 2010; 12: 39-46.
23. Sobotka PA, Krum H, Böhm M, Francis DP, Schlaich MP. The role of renal denervation in the treatment of heart failure. Curr Cardiol Rep 2012; 14: 285-292.
24. Ventura HO. Benefits of patient in initiation of beta-blockers. Am Heart J 2004; 148: 944-950.
25. Souza DR, Mill JG, Cabral AM. Chronic experimental myocardial infarction produces antinatriuresis by a renal nerve-dependent mechanism. Braz J Med Biol Res 2004; 37: 285-293.
26. Nozawa T, Igawa A, Fujii N, Kato B, Yoshida N, Asanoi H, et al. Effect of long term renal sympathetic denervation on heart failure after myocardial infarction in rats. Heart Vessels 2002; 16: 51-56.
27. Ukena C, Bauer A, Mahfoud F, Schreieck J, Neuberger HR, Eick C, et al. Renal sympathetic denervation for treatment of electneal storm: first-m-man experience. Clin Res Cardiol 2012;101:63-67.
28. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J 2012; 33: 1058-1066.